| Literature DB >> 27063952 |
Bo Halle1,2,3, Mads Thomassen4,5, Ranga Venkatesan6, Vivek Kaimal6, Eric G Marcusson6, Sune Munthe7,8,4, Mia D Sørensen7,4, Charlotte Aaberg-Jessen9, Stine S Jensen7,4, Morten Meyer10, Torben A Kruse4,5, Helle Christiansen11, Steffen Schmidt11, Jan Mollenhauer11, Mette K Schulz8,4, Claus Andersen8,4, Bjarne W Kristensen7,4.
Abstract
Glioblastomas always recur despite surgery, radiotherapy and chemotherapy. A key player in the therapeutic resistance may be immature tumor cells with stem-like properties (TSCs) escaping conventional treatment. A group of promising molecular targets are microRNAs (miRs). miRs are small non-coding RNAs exerting post-transcriptional regulation of gene expression. In this study we aimed to identify over-expressed TSC-related miRs potentially amenable for therapeutic targeting. We used non-differentiated glioblastoma spheroid cultures (GSCs) containing TSCs and compared these to xenografts using a NanoString nCounter platform. This revealed 19 over-expressed miRs in the non-differentiated GSCs. Additionally, non-differentiated GSCs were compared to neural stem cells (NSCs) using a microarray platform. This revealed four significantly over-expressed miRs in the non-differentiated GSCs in comparison to the NSCs. The three most over-expressed miRs in the non-differentiated GSCs compared to xenografts were miR-126, -137 and -128. KEGG pathway analysis suggested the main biological function of these over-expressed miRs to be cell-cycle arrest and diminished proliferation. To functionally validate the profiling results suggesting association of these miRs with stem-like properties, experimental over-expression of miR-128 was performed. A consecutive limiting dilution assay confirmed a significantly elevated spheroid formation in the miR-128 over-expressing cells. This may provide potential therapeutic targets for anti-miRs to identify novel treatment options for GBM patients.Entities:
Keywords: Cancer stem cell; Glioblastoma; MicroRNA; Tumor stem cell
Mesh:
Substances:
Year: 2016 PMID: 27063952 DOI: 10.1007/s11060-016-2125-x
Source DB: PubMed Journal: J Neurooncol ISSN: 0167-594X Impact factor: 4.130